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LAM-IV-110 Healthy volunteers with food (N = 35)
LAM-IV-110 Healthy volunteers after food (N = 35)
LAM-IV-111 Healthy volunteers (N = 8)
SPD405-117 Healthy volunteers (N = 8)
LAM-IV-111 Dialysis patients (N = 9)
Fig. 1. Mean plasma lanthanum concentra-
tion profiles in healthy volunteers and dial-
ysis patients after a single oral dose of lan-
thanum carbonate (Fosrenol; 4 × 250-mg
chewable tablets) in Phase I clinical stud-
ies. Study LAM-IV-110: Phase I, open-label,
randomized, 2-way crossover study compar-
ing lanthanum carbonate administered dur-
ing, and after food in healthy subjects. Study
LAM-IV-111: Phase I, open-label, single- and
multiple-dose study comparing lanthanum
pharmacokinetics in dialysis patients and
healthy subjects. Study SPD405-117: single-
dose, open-label, parallel group study to as-
sess lanthanum pharmacokinetics after oral
and intravenous dosing in healthy male sub-
jects. Poster presentation at ASN 2003 [5], full
publications in preparation.
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Reply from the Authors
D’Haese et al take issue with our statement that there
are important differences in the pharmacokinetics of lan-
thanum in chronic renal failure (CRF), compared with
the normal state. This statement was based on our finding
of a significantly higher degree of tissue lanthanum accu-
mulation in CRF rats than in rats with normal renal func-
tion in response to high oral lanthanum doses, as reported
in a recent issue of Kidney International [1]. Authors state
that plasma lanthanum kinetics after an acute oral dose
of lanthanum carbonate were similar in healthy subjects
and dialysis patients. However, on closer scrutiny of their
Figure, it is clear that only the LAM-IV-III study deals
with this issue. The other three kinetics studies are not
directly related. Surprisingly, the plasma kinetics of the
healthy volunteers and the dialysis patients in the LAM-
IV-III study look quite different, with markedly higher
plasma lanthanum concentrations over time in the latter
and no overlap. Moreover, even if there was no signifi-
cant difference between the healthy and uremic subjects
in response to an acute oral lanthanum dose, this does not
exclude the possibility of enhanced tissue accumulation
of lanthanum in the uremic state after long-term adminis-
tration. Increased intestinal absorption is almost certainly
involved in the enhanced tissue lanthanum accumulation
associated with the uremic state. This can be deduced
from our observation of a significantly higher urinary lan-
thanum excretion in the 5/6 nephrectomy model of CRF
rats, together with an increase in lanthanum content in
various tissues [1].
Sample contamination can be reasonably excluded
because we found lanthanum concentrations in bone
tissue comparable to those reported for CRF rats by
the Antwerp group [2]. Of note, if contamination by
lanthanum contained in food played an important role,
this should have led to a similar increase of urinary
lanthanum excretion in non-CRF as in CRF rats be-
cause these two groups of animals were exposed to
same lanthanum-enriched diet. This is, in our opin-
ion, another strong argument against the contamination
hypothesis.
The fact that the Antwerp group administered lan-
thanum carbonate by gavage at daytime [2] probably ex-
plains why they failed to observe a significant reduction
in plasma phosphorus because rats eat only during night-
time. Instead, our mode of administering lanthanum car-
bonate together with the diet almost certainly explains
why we were able to observe a significant phosphorus-
lowering effect because the animals ingested the phos-
phate binder together with their meals. As to the very
high plasma lanthanum levels reported in the rats of our
study, regrettably these are due to a transcription error
of the units transmitted by the laboratory. They should
read lg/L instead of lg/mL, as outlined in more detailed
fashion in our reply to McLeod et al.
Finally, we feel that studies in animals are useful to
anticipate possible problems with new drugs before their
widespread administration to human beings.
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Table 1. Absolute (mg) and body weight adjusted (mg/g) liver and kidney weights in normal and uremic rats
Treatment group Body weight (g)a Liver wt (mg) Liver wt (mg/g) Kidney wt (mg) Kidney wt (mg/g)
La[−] control 472 11,632 24.6 1489 3.2
La[+] control 463 11,004 23.8 1430 3.1
La[−] adenine 340 9003 26.5 2420 7.1
La[+] adenine 307 7114 23.2 2092 6.8
La[−] Nx 330 8899 27.0 810 2.5
La[+] Nx 307 7829 25.5 727 2.4
Abbreviations: [−], no lanthanum treatment; [+], 3% lanthanum in diet; Nx, 5/6th nephrectomized renal failure model; adenine, adenine induced renal failure model
(adenine given 0.3% of diet); control, normal renal function. Body weight adjustment abolishes differences in organ weight between lanthanum-treated and -untreated
groups within each renal failure model.
aNonfasted preterminal body weight (day 38) extracted from Figure 1 of Lacour et al [1].
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The need for careful
interpretation of animal data
on lanthanum
To the Editor: Lacour et al [1] describe reductions in
organ weights in uremic rats given lanthanum carbon-
ate, those for liver and kidney being highlighted as sig-
nificant because differences remained after normalisa-
tion for femur length. Adjustment using femur length
is unconventional, as drug effects on body mass (un-
less they affect growth) do not influence this parameter.
Normalization using body mass is the standard method,
and in our view should have been used due to the dif-
ferences in body weight between lanthanum-treated and
-untreated rats. When kidney and liver weights are nor-
malized in this way, group differences are abolished (see
Table 1 above).
The authors also note qualitative differences in tissue
lanthanum deposition between normal and uremic rats,
and between different uremia models. No hypotheses
were put forward to suggest why lanthanum might de-
posit in brain, heart, and skeletal muscle in one disease
model, but not in another, or in normal rats. The extent
to which these differences were artefacts of contamina-
tion is unclear, as lanthanum was administered at very
high concentrations in the diet (probably powdered), and
plasma concentrations were extraordinarily high both in
control and lanthanum-treated groups [2]. Lung depo-
sition is also unusual in our experience and may reflect
inhalation of lanthanum from the diet. Furthermore, the
authors report major intestinal pathology in the adenine
uremia model, but not the nephrectomized model, yet
paradoxically rule out any influence of this on the ab-
sorption and deposition of lanthanum.
Extrapolation of the Lacour et al [1] findings to human
lanthanum exposure appears unwarranted at this time.
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Reply from the Authors
We agree with Rambeck that the usual way of compar-
ing organ weights of uremic animals with those of nor-
mal animals is normalization for body mass, not femur
length. However, because in our study we happened to
observe markedly lower liver weights in the two animal
groups with chronic renal failure (CRF) fed on lanthanum
carbonate, we compared CRF rats receiving lanthanum
treatment with CRF rats receiving no lanthanum treat-
ment [1]. Thus, in doing this analysis we did not compare
CRF rats with normal rats. Because total body weights
were also slightly decreased in the two groups of CRF
rats that received lanthanum supplements, as compared
to those CRF rat groups receiving no lanthanum sup-
plements, we reasoned that the changes in liver weight
should be better normalized using total femur length,
which remained the same, than using total body weight,
